Venetoclax: A New Hope for Elderly Patients with Acute Myeloid Leukemia


  • Bárbara Marques Serviço de Hematologia Clínica. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Carolina Afonso Serviço de Hematologia Clínica. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Emília Cortesão Serviço de Hematologia Clínica. Centro Hospitalar e Universitário de Coimbra. Coimbra.



Aged, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute/drug therapy


Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by clonal proliferation, with increased incidence with advancing age. AML with myelodysplasia-related changes (AML-MRC) represents an AML subtype with a poor prognosis and challenging treatment, particularly in elderly patients. We report the case of a 77-year-old patient diagnosed with high-risk AML-MRC, ineligible for intensive chemotherapy, with frequent need of transfusion of red cell concentrates. The authors present, to the best of their knowledge, the first patient in Portugal with AML-MRC treated with an hypomethylating agent, azacytidine, and a BCL2 inhibitor (venetoclax), and that association was essential in the treatment and overall survival, which was much higher than expected.


Download data is not yet available.


Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52. DOI:

Juliusson G, Abrahamsson J, Lazarevic V, Antunovic P, Derolf, Garelius H, et al. Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden. Leukemia. 2017;31:728–31. DOI:

Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva I, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study. J Clin Oncol. 2015;33:3641–9. DOI:

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. DOI:

Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:697–712. DOI:

Arber DA, Erba HP. Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). Am J Clin Pathol. 2020;154:731–41. DOI:

Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–9. DOI:

Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B. AML with myelodysplasia-related changes: Development, challenges, and treatment advances. Genes. 2020;11:1–13. DOI:

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. DOI:

Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012;91:1861–70. DOI:

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatmentnaive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17. DOI:

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617–29. DOI:



How to Cite

Marques B, Afonso C, Cortesão E. Venetoclax: A New Hope for Elderly Patients with Acute Myeloid Leukemia. Acta Med Port [Internet]. 2022 Mar. 29 [cited 2023 Feb. 7];36(1):59-62. Available from:



Case Report